Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385522075> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W4385522075 abstract "Currently approved therapies for individuals with alpha-1 antitrypsin deficiency (AATD) are intravenously infused products. The burdens and demographics of infusion practices in the United States are not well characterized.What is the prevalence of different infusion practices in the United States?AlphaNet disease management participants completed a survey that captured current and past infusion practices. Reasons for choosing their current infusion practice, problems with past infusion practices, resources required, and support services utilized were collected from February 8, 2022, through July 1, 2022.Among 5266 individuals, infusions happened at home by health care providers (60.2%), at infusion clinics (30.6%), and by self-infusion (8.1%). Self-infusion prevalence increased with time on therapy and was more prevalent in younger individuals (61.2 ± 10.5 years) compared to users of other infusion practices (64.1 ± 11.0 years), (p<0.001). Perceived benefits of self-infusion included freedom and flexibility (77.9%), ability to travel (44.5%), avoidance of infusion clinics (41.8%), time-savings (35.9%), less absence from work (26.6%), less exposure to infections (22.1%), and less cost (16.4%). Self-infusion was done through permanent intravenous catheters in 41.2% and peripheral intravenous catheters by 58.3%. Self-infusers were more satisfied (93.1% very satisfied) than other groups. Among individuals currently infusing with home nurses or in clinics, 21.4% would consider self-infusions in the future.Self-infusion of alpha-1 antitrypsin is feasible and associated with high satisfaction scores. Recommendations for catheter care, infusion support, and cost management are informed by survey results." @default.
- W4385522075 created "2023-08-04" @default.
- W4385522075 creator A5006886866 @default.
- W4385522075 creator A5049946088 @default.
- W4385522075 creator A5057800275 @default.
- W4385522075 creator A5064431969 @default.
- W4385522075 creator A5072877323 @default.
- W4385522075 date "2023-01-01" @default.
- W4385522075 modified "2023-09-26" @default.
- W4385522075 title "Augmentation Therapy for Alpha-1 Antitrypsin Deficiency: Patient Experiences with Self-Infusion, Home Providers, and Clinics" @default.
- W4385522075 doi "https://doi.org/10.15326/jcopdf.2023.0430" @default.
- W4385522075 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37549313" @default.
- W4385522075 hasPublicationYear "2023" @default.
- W4385522075 type Work @default.
- W4385522075 citedByCount "0" @default.
- W4385522075 crossrefType "journal-article" @default.
- W4385522075 hasAuthorship W4385522075A5006886866 @default.
- W4385522075 hasAuthorship W4385522075A5049946088 @default.
- W4385522075 hasAuthorship W4385522075A5057800275 @default.
- W4385522075 hasAuthorship W4385522075A5064431969 @default.
- W4385522075 hasAuthorship W4385522075A5072877323 @default.
- W4385522075 hasBestOaLocation W43855220751 @default.
- W4385522075 hasConcept C141071460 @default.
- W4385522075 hasConcept C144024400 @default.
- W4385522075 hasConcept C149923435 @default.
- W4385522075 hasConcept C159110408 @default.
- W4385522075 hasConcept C177713679 @default.
- W4385522075 hasConcept C194828623 @default.
- W4385522075 hasConcept C2775944032 @default.
- W4385522075 hasConcept C2778555786 @default.
- W4385522075 hasConcept C2779352459 @default.
- W4385522075 hasConcept C2780084366 @default.
- W4385522075 hasConcept C2780608335 @default.
- W4385522075 hasConcept C2781267111 @default.
- W4385522075 hasConcept C2911027401 @default.
- W4385522075 hasConcept C42219234 @default.
- W4385522075 hasConcept C71924100 @default.
- W4385522075 hasConceptScore W4385522075C141071460 @default.
- W4385522075 hasConceptScore W4385522075C144024400 @default.
- W4385522075 hasConceptScore W4385522075C149923435 @default.
- W4385522075 hasConceptScore W4385522075C159110408 @default.
- W4385522075 hasConceptScore W4385522075C177713679 @default.
- W4385522075 hasConceptScore W4385522075C194828623 @default.
- W4385522075 hasConceptScore W4385522075C2775944032 @default.
- W4385522075 hasConceptScore W4385522075C2778555786 @default.
- W4385522075 hasConceptScore W4385522075C2779352459 @default.
- W4385522075 hasConceptScore W4385522075C2780084366 @default.
- W4385522075 hasConceptScore W4385522075C2780608335 @default.
- W4385522075 hasConceptScore W4385522075C2781267111 @default.
- W4385522075 hasConceptScore W4385522075C2911027401 @default.
- W4385522075 hasConceptScore W4385522075C42219234 @default.
- W4385522075 hasConceptScore W4385522075C71924100 @default.
- W4385522075 hasLocation W43855220751 @default.
- W4385522075 hasLocation W43855220752 @default.
- W4385522075 hasOpenAccess W4385522075 @default.
- W4385522075 hasPrimaryLocation W43855220751 @default.
- W4385522075 hasRelatedWork W1510491287 @default.
- W4385522075 hasRelatedWork W2111766121 @default.
- W4385522075 hasRelatedWork W2138607856 @default.
- W4385522075 hasRelatedWork W2348307856 @default.
- W4385522075 hasRelatedWork W2354863993 @default.
- W4385522075 hasRelatedWork W2355521429 @default.
- W4385522075 hasRelatedWork W2373441431 @default.
- W4385522075 hasRelatedWork W3031203941 @default.
- W4385522075 hasRelatedWork W4246528917 @default.
- W4385522075 hasRelatedWork W2561877432 @default.
- W4385522075 isParatext "false" @default.
- W4385522075 isRetracted "false" @default.
- W4385522075 workType "article" @default.